Archive for 'Publicaciones'

Alvarez XA, Alvarez I, Iglesias O, Crespo I, Figueroa J, Aleixandre M, Linares C, Granizo E, Garcia-Fantini M, Marey J, Masliah E, Winter S, Muresanu D, Moessler H. Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases.
International Journal of Neuropsychopharmacology 2016;
doi: 10.1093/ijnp/pyw024

Muresanu DF, Ciurea AV, Gorgan RM, Gheorghita E, Florian SI, Stan H, Blaga A, Ianovici N, Iencean SM, Turliuc D, Davidescu HB, Mihalache C, Brehar FM, Mihaescu AS, Mardare DC, Anghelescu A, Chiparus C, Lapadat M, Pruna V, Mohan D, Costea C, Costea D, Palade C, Bucur N, Figueroa J, Alvarez A. A retrospective, multi-center cohort study evaluating the severity- related effects of cerebrolysin treatment on clinical outcomes in traumatic brain injury. CNS Neurol Disord Drug Targets 2015;14(5):587-599.

Alvarez XA, Aleixandre M, Linares C, Masliah E, Moessler H. Apathy and APOE4 are associated with reduced BDNF levels in Alzheimer’s disease. Journal of Alzheimer’s Disease 2014; 42:1347-1355

Alvarez XA, Figueroa J, Muresanu D. Peptidergic drugs for treatment of traumatic brain injury. Future Neurology 2013;8(2):175–192

Alvarez XA, Linares C, Masliah E. Combination drug therapy for the treatment of Alzheimer’s disease. European Neurological Review 2012;7(2):92–102

Alvarez XA, Fuentes P. Cerebrolysin in Alzheimer’s disease. Drugs Today 2011;47(7):487-513.

Rockenstein E, Ubhi K, Pham E, Michael S, Doppler E, Novak P, Inglis C, Mante M, Adame A, Alvarez XA, Moessler H, Masliah E. Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer’s disease. J Neurosci Res 2011;89(11):1812-21.

Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E, Doppler E, Moessler H. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer_s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurology 2011;18:59-68.

Alvarez XA, Cacabelos R, Sampedro C, Couceiro V, Aleixandre M, Vargas M, Linares C, Granizo E, García-Fantini M, Beurecht W, Doppler E, Moessler H. Combination Treatment in Alzheimer’s Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil. Current Alzheimer Research 2011; 8:593-591

Muresanu DF, Alvarez XA, Moessler H, Novak PH, Stan A, Buzoianu A, Bajenaru O, Popescu BO. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study. J Neurol Sci 2010;299(1-2):179-183.